Business Standard

Biocon Ltd News

Biocon gets EMA's nod to make biosimilar cancer drug at Bengaluru

Bevacizumab is used to treat colon and rectal cancer, cervical cancer etc

Biocon gets EMA's nod to make biosimilar cancer drug at Bengaluru
Updated On : 24 Jun 2024 | 3:04 PM IST

Biocon searches for partner to test generic Wegovy, Ozempic in China

Biocon's generics would join at least 15 other generics or biosimilars in development by Chinese drugmakers ahead of an expiry of patent protection on semaglutide

Biocon searches for partner to test generic Wegovy, Ozempic in China
Updated On : 20 Jun 2024 | 3:54 PM IST

Biocon Biologics announces getting US FDA approval for eye treatment drug

Company says approval is a 'significant milestone' and marks entry in new therapeutic area in the US

Biocon Biologics announces getting US FDA approval for eye treatment drug
Updated On : 21 May 2024 | 11:22 AM IST

Biocon Q4 results: Net profit falls 57% to Rs 136 crore; revenue up 0.94%

Biocon has re-appointed Kiran Mazumdar Shaw as an Executive Director of the company for a further period of 5 years starting April 2025

Biocon Q4 results: Net profit falls 57% to Rs 136 crore; revenue up 0.94%
Updated On : 16 May 2024 | 9:12 PM IST

Biocon Q4 results: Profit drops 57% to Rs 135 crore; revenue up 4%

Biocon Q4FY24 results: The company board has recommended a final dividend at the rate of 10 per cent i.e. Re. 0.50 per equity share

Biocon Q4 results: Profit drops 57% to Rs 135 crore; revenue up 4%
Updated On : 16 May 2024 | 5:53 PM IST

Biocon signs deal with Biomm SA to commercialise diabetes drug in Brazil

Biomm SA develops and commercialises complex biotech and biosimilar drug products

Biocon signs deal with Biomm SA to commercialise diabetes drug in Brazil
Updated On : 18 Apr 2024 | 12:25 PM IST

Biocon partners Biomm SA to commercialise it's diabetes drug in Brazil

Biotechnology firm Biocon on Wednesday said it has tied up with Brazil-based Biomm SA for the commercialisation of its diabetes drug in the Latin American nation. Under the terms of the agreement, Biocon will undertake the development, manufacturing and supply of Semaglutide (gOzempic), and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market. Biomm focuses on developing, manufacturing and commercialising complex biotech and biosimilar drug products at its production facility in Nova Lima. "Our partnership with Biomm marks another important step forward in our strategy to expand our global footprint beyond the US and Europe for Peptides," Biocon CEO and MD Siddharth Mittal said in a statement. This is also in line with the growth strategy of bringing to market a portfolio of complex, GLP-1 drug-device combination products, he added. "We are confident that our collaboration with Biomm will provide patients in Brazil, who are livi

Biocon partners Biomm SA to commercialise it's diabetes drug in Brazil
Updated On : 17 Apr 2024 | 9:47 PM IST

Biocon leads India's push into anti-obesity drugs as patents lapse

The company, helmed by Kiran Mazumdar Shaw, is leading the charge among Indian drugmakers - the world's largest supplier of generic medicines - as they race to grab a slice of the obesity drugs market

Biocon leads India's push into anti-obesity drugs as patents lapse
Updated On : 08 Apr 2024 | 6:30 AM IST

Stocks to Watch: Healthcare, Titan, UB, Wipro, Zee, Voda Idea, Adani group

Stocks to watch on Monday, April 08, 2024: Shares of healthcare related firms likely to be in focus as Manipal nears acquisition of Medica Synergie.

Stocks to Watch: Healthcare, Titan, UB, Wipro, Zee, Voda Idea, Adani group
Updated On : 08 Apr 2024 | 7:34 AM IST

Eris buys India formulation biz of Biocon Biologics for Rs 1,242 crore

The deal would enable Eris' entry into the Rs 3k cr injectables market, and it would become one of major players in the insulins segment with the acquisition of Biocon Biologic's Basalog and Insugen

Eris buys India formulation biz of Biocon Biologics for Rs 1,242 crore
Updated On : 14 Mar 2024 | 8:43 PM IST

Biocon to sell branded formulations biz to Eris Lifesciences for $150 mn

Biocon had earlier sold its dermatology and nephrology branded formulation businesses to Eris for Rs 350 crore in November last year

Biocon to sell branded formulations biz to Eris Lifesciences for $150 mn
Updated On : 14 Mar 2024 | 5:17 PM IST

Biocon Biologics gets green light to launch Yesafili biosimilar in Canada

Under the agreement, Biocon Biologics will launch Yesafili no later than July 1, 2025. Health Canada had granted tentative approval for Yesafili in March 2023

Biocon Biologics gets green light to launch Yesafili biosimilar in Canada
Updated On : 04 Mar 2024 | 4:29 PM IST

Biocon Biologics signs agreement with Janssen Biotech for psoriasis drug

Biocon said that the U.S. FDA has accepted the Biologics License Application (BLA) for Bmab 1200 (bUstekinumab) for review under the 351(k) pathway

Biocon Biologics signs agreement with Janssen Biotech for psoriasis drug
Updated On : 29 Feb 2024 | 8:22 PM IST

Biocon receives a penalty of over Rs 3 crore in GST related issues

Biocon Ltd on Friday said it has been imposed a penalty of over Rs 3 crore over GST-related issues. The company has received an order of adjudication imposing a penalty of Rs 3,03,78,465 dated February 22, 2024, from the office of Deputy Commissioner of Commercial Taxes, Divisional GST Office, Bangalore, Biocon Ltd said in a regulatory filing. The demand is related to input tax credit reporting error in GST monthly returns, denial of input tax credit on sales and promotional expenditures, valuation issue GST under corporate guarantee, and denial of exemption on export of services, it added. Biocon further said it is "in the process of taking appropriate actions, including but not limited to, filing of the necessary appeal with the appellate authority in this regard". There is no material impact on the financials, operations or other activities of the company, the filing said.

Biocon receives a penalty of over Rs 3 crore in GST related issues
Updated On : 23 Feb 2024 | 5:10 PM IST

In next 4-5 years, we aim capex of Rs 1,500 cr: Biocon's Siddharth Mittal

Siddharth Mittal outlines the growth strategies and challenges ahead

In next 4-5 years, we aim capex of Rs 1,500 cr: Biocon's Siddharth Mittal
Updated On : 11 Feb 2024 | 6:39 PM IST

Biocon Biologics partners with Sandoz Australia to sell cancer drugs

The partnership will provide Sandoz the exclusive rights to promote, sell, and distribute biosimilar Trastuzumab and biosimilar Bevacizumab in Australia

Biocon Biologics partners with Sandoz Australia to sell cancer drugs
Updated On : 09 Feb 2024 | 12:02 PM IST

Biocon inks pact with Sandoz for sale of 2 biosimilar products in Australia

Biocon Biologics on Friday said it has inked a five-year pact with pharmaceutical company Sandoz AG regarding the sale and distribution of two cancer treatment biosimilar products in Australia. The agreement provides Sandoz the exclusive rights to promote, sell and distribute biosimilars Trastuzumab and Bevacizumab in Australia, Biocon Biologics said in a statement. Biocon Biologics is a subsidiary of Biocon Ltd. Under the agreement, Sandoz will distribute the Biocon Biologics' brands, Ogivri (Trastuzumab) and Abevmy (Bevacizumab), and facilitate the sustained access of these medications that were previously distributed by another pharmaceutical company to patients in Australia. Trastuzumab is a biosimilar of Herceptin and Bevacizumab is a biosimilar of Avastin and utilised for the treatment of various cancers. "Following the recent establishment of our strategic partnership with Sandoz in Japan, our agreement with Sandoz in Australia marks another important milestone of our globa

Biocon inks pact with Sandoz for sale of 2 biosimilar products in Australia
Updated On : 09 Feb 2024 | 11:21 AM IST

Biocon Q3FY24 results: Net profit at Rs 660 crore, revenue up 50%

Biocon's overall growth was boosted by the conclusion of the transition of the acquired business by Biocon Biologics and pre-payment of $200 million towards the acquisition-related debt reduction

Biocon Q3FY24 results: Net profit at Rs 660 crore, revenue up 50%
Updated On : 08 Feb 2024 | 9:49 PM IST

Biocon gets USFDA approval to market generic anti-cancer medication

Biocon Ltd on Tuesday said it has received approval from the US health regulator for a generic anti-cancer medication. The company has received approval from the US Food and Drug Administration (USFDA) for Dasatinib tablets to market in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, Biocon said in a regulatory filing. The approval will further strengthen the company's portfolio of vertically integrated, complex drug products, it added. Shares of Biocon settled 4.97 per cent higher at Rs 298.75 apiece on the BSE.

Biocon gets USFDA approval to market generic anti-cancer medication
Updated On : 06 Feb 2024 | 8:41 PM IST

Pharma sector can be of $200 bn by 2030 on innovative drugs: Biocon chief

Research-based incentives to develop innovative drugs can help the domestic pharmaceutical sector to be worth USD 200 billion by 2030, Biocon Executive Chairperson Kiran Mazumdar-Shaw said on Wednesday. Terming the pharmaceutical sector as a great contributor in the country's economic growth, she noted that the industry has even greater potential to grow in the years to come. "India's pharma industry size is estimated at about USD 65 billion today. And by 2030, it is expected to increase to USD 165 billion. Now, I believe it has a potential to even be greater and touch USD 200 billion by 2030," Mazumdar-Shaw told PTI. But such a level of growth cannot just be driven by generics and biosimilars, it has to involve drug innovation, she noted. "We have time to develop new drugs which could be blockbusters and I think what is required are research incentives to drive this kind of growth," Mazumdar-Shaw stated. The government has already come out with various research-linked incentive .

Pharma sector can be of $200 bn by 2030 on innovative drugs: Biocon chief
Updated On : 25 Jan 2024 | 12:19 AM IST